Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G, Frahm I, Allemand DH, Deza EG, Ares S, Gercovich FG, Guzmán P, Roa JC, Elizalde PV, Schillaci R. Mercogliano MF, et al. Among authors: elizalde pv. Clin Cancer Res. 2017 Feb 1;23(3):636-648. doi: 10.1158/1078-0432.CCR-16-0970. Epub 2016 Oct 3. Clin Cancer Res. 2017. PMID: 27698002
Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.
Puricelli L, Proietti CJ, Labriola L, Salatino M, Balañá ME, Aguirre Ghiso J, Lupu R, Pignataro OP, Charreau EH, Bal de Kier Joffé E, Elizalde PV. Puricelli L, et al. Among authors: elizalde pv. Int J Cancer. 2002 Aug 20;100(6):642-53. doi: 10.1002/ijc.10533. Int J Cancer. 2002. PMID: 12209601
Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
Labriola L, Salatino M, Proietti CJ, Pecci A, Coso OA, Kornblihtt AR, Charreau EH, Elizalde PV. Labriola L, et al. Among authors: elizalde pv. Mol Cell Biol. 2003 Feb;23(3):1095-111. doi: 10.1128/MCB.23.3.1095-1111.2003. Mol Cell Biol. 2003. PMID: 12529413 Free PMC article.
Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M, Schillaci R, Proietti CJ, Carnevale R, Frahm I, Molinolo AA, Iribarren A, Charreau EH, Elizalde PV. Salatino M, et al. Among authors: elizalde pv. Oncogene. 2004 Jul 1;23(30):5161-74. doi: 10.1038/sj.onc.1207659. Oncogene. 2004. PMID: 15122317
Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells.
Proietti C, Salatino M, Rosemblit C, Carnevale R, Pecci A, Kornblihtt AR, Molinolo AA, Frahm I, Charreau EH, Schillaci R, Elizalde PV. Proietti C, et al. Among authors: elizalde pv. Mol Cell Biol. 2005 Jun;25(12):4826-40. doi: 10.1128/MCB.25.12.4826-4840.2005. Mol Cell Biol. 2005. PMID: 15923602 Free PMC article.
Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway.
Schillaci R, Salatino M, Cassataro J, Proietti CJ, Giambartolomei GH, Rivas MA, Carnevale RP, Charreau EH, Elizalde PV. Schillaci R, et al. Among authors: elizalde pv. J Immunol. 2006 Mar 15;176(6):3426-37. doi: 10.4049/jimmunol.176.6.3426. J Immunol. 2006. PMID: 16517711
Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation.
Salatino M, Beguelin W, Peters MG, Carnevale R, Proietti CJ, Galigniana MD, Vedoy CG, Schillaci R, Charreau EH, Sogayar MC, Elizalde PV. Salatino M, et al. Among authors: elizalde pv. Oncogene. 2006 Dec 14;25(59):7723-39. doi: 10.1038/sj.onc.1209757. Epub 2006 Jun 26. Oncogene. 2006. PMID: 16799639
Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.
Carnevale RP, Proietti CJ, Salatino M, Urtreger A, Peluffo G, Edwards DP, Boonyaratanakornkit V, Charreau EH, Bal de Kier Joffé E, Schillaci R, Elizalde PV. Carnevale RP, et al. Among authors: elizalde pv. Mol Endocrinol. 2007 Jun;21(6):1335-58. doi: 10.1210/me.2006-0304. Epub 2007 Apr 17. Mol Endocrinol. 2007. PMID: 17440047
68 results